Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20267 Citations
Larazotide (AT-1001)8 residuesGGVLVQPGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Larazotide acetate is an oral peptide that blocks zonulin-mediated tight junction opening in the gut. Phase 2b showed 26% fewer symptomatic days in celiac patients, though Phase 3 failed at interim analysis. No injection required. Safety matched placebo closely.
0.5mcg · 3x Daily
Summary: Add 0mL BAC water to your 0.5mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.5mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.5mg | 3x Daily |
| Moderate | 0.5mg | 3x Daily |
| Aggressive | 0.5mg | 3x Daily |
Larazotide is oral. No vials, no bacteriostatic water, no syringes. You're swallowing a capsule, 0.5 mg, three times a day, 15 minutes before meals. Timing matters more than most people expect. The capsule needs to be in the lumen before gliadin-derived peptides arrive. Taking it with food instead of before food likely reduces the protective window. Formulation is the real variable here. Clinical trials used delayed-release capsules engineered to dissolve in the duodenum and proximal jejunum. Raw API powder dumped into a standard gelatin capsule may release in the stomach and never reach the target site. If you're sourcing from a research supplier, delayed-release encapsulation is not optional. Don't escalate the dose. Phase 2b tested 0.5 mg, 1 mg, and 2 mg TID. The 1 mg and 2 mg groups performed no better than placebo. The working hypothesis is receptor saturation causing paradoxical loss of efficacy; 0.5 mg TID is the ceiling. Store capsules at room temperature (20 to 25 degrees Celsius). Stable for 24 months when kept dry.
Dosing based on Phase 2b trial: larazotide acetate in celiac disease (CeliAction) — 10 published references.View all sources →
Cross-check your Larazotide (AT-1001) reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Larazotide acetate is an oral peptide that blocks zonulin-mediated tight junction opening in the gut. Phase 2b showed 26% fewer symptomatic days in celiac patients, though Phase 3 failed at interim analysis. No injection required. Safety matched placebo closely.
